Verastem (VSTM) Gross Profit (2018 - 2026)

Verastem's (VSTM) quarterly Gross Profit came in at $15.9 million in Q1 2026, up 6.54% quarter-over-quarter from $14.9 million in Q4 2025.

Verastem (VSTM) Gross Profit (2018 - 2026) Analysis & Trends

Verastem's Gross Profit history runs 5 years deep, the most recent figure standing at $15.9 million for Q1 2026.

On a quarterly basis, Gross Profit changed N/A year-over-year to $15.9 million in Q1 2026; TTM through Mar 2026 was $42.2 million, a N/A change from a year earlier, with the FY2025 full-year figure at $26.3 million, changed N/A from the prior year.
Gross Profit climbed to $15.9 million in Q1 2026 per VSTM's latest filing, from $14.9 million in the prior quarter.
Across five years, Gross Profit topped out at $15.9 million in Q1 2026 and bottomed at $1.8 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Verastem	166.09 Mn	-31.73 Mn	15.90 Mn

Download Data